Roche and Genentech have ironed out their differences and announced this morning a friendly deal in which Roche will be buying the 44 percent of Genentech it doesn't already own for $95 a share, reports Agence France-Presse.
Roche and Genentech have ironed out their differences and announced this morning a friendly deal in which Roche will be buying the 44 percent of Genentech it doesn't already own for $95 a share, reports Agence France-Presse.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.